229 related articles for article (PubMed ID: 25574844)
1. Magnolol Inhibits RANKL-induced osteoclast differentiation of raw 264.7 macrophages through heme oxygenase-1-dependent inhibition of NFATc1 expression.
Lu SH; Chen TH; Chou TC
J Nat Prod; 2015 Jan; 78(1):61-8. PubMed ID: 25574844
[TBL] [Abstract][Full Text] [Related]
2. RANKL-induced osteoclastogenesis is suppressed by 4-O-methylhonokiol in bone marrow-derived macrophages.
Park KR; Kim JY; Kim EC; Yun HM; Hong JT
Arch Pharm Res; 2017 Aug; 40(8):933-942. PubMed ID: 28736799
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
4. Activation of Nrf2/HO-1signaling pathway involves the anti-inflammatory activity of magnolol in Porphyromonas gingivalis lipopolysaccharide-stimulated mouse RAW 264.7 macrophages.
Lu SH; Hsu WL; Chen TH; Chou TC
Int Immunopharmacol; 2015 Dec; 29(2):770-778. PubMed ID: 26388191
[TBL] [Abstract][Full Text] [Related]
5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
6. Magnolol Inhibits Osteoclast Differentiation via Suppression of RANKL Expression.
Hwang YH; Kim T; Kim R; Ha H
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004401
[TBL] [Abstract][Full Text] [Related]
7. Sargassum serratifolium attenuates RANKL-induced osteoclast differentiation and oxidative stress through inhibition of NF-κB and activation of the Nrf2/HO-1 signaling pathway.
Kim HJ; Park C; Kim GY; Park EK; Jeon YJ; Kim S; Hwang HJ; Choi YH
Biosci Trends; 2018; 12(3):257-265. PubMed ID: 30012915
[TBL] [Abstract][Full Text] [Related]
8. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
11. Heme oxygenase-1 (HO-1)/carbon monoxide (CO) axis suppresses RANKL-induced osteoclastic differentiation by inhibiting redox-sensitive NF-κB activation.
Bak SU; Kim S; Hwang HJ; Yun JA; Kim WS; Won MH; Kim JY; Ha KS; Kwon YG; Kim YM
BMB Rep; 2017 Feb; 50(2):103-108. PubMed ID: 28088947
[TBL] [Abstract][Full Text] [Related]
12. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
Huh JE; Lee WI; Kang JW; Nam D; Choi DY; Park DS; Lee SH; Lee JD
J Nat Prod; 2014 Nov; 77(11):2423-31. PubMed ID: 25397676
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
14. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
15. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
16. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
[TBL] [Abstract][Full Text] [Related]
18. Magnolol inhibits lipopolysaccharide-induced inflammatory response by interfering with TLR4 mediated NF-κB and MAPKs signaling pathways.
Fu Y; Liu B; Zhang N; Liu Z; Liang D; Li F; Cao Y; Feng X; Zhang X; Yang Z
J Ethnopharmacol; 2013 Jan; 145(1):193-9. PubMed ID: 23127653
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
20. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
